OpenAI 将从客户人工智能辅助研发成果中抽取一定比例。
OpenAI to Take a Percentage from Customer AI-Assisted R&D Outcomes

原始链接: https://news.aibase.com/news/24859

OpenAI 正在探索一种潜在的革命性商业模式:分享由其人工智能工具产生的收益。该计划目前正在内部讨论中,目标是像制药和材料科学等高研发投入的行业。OpenAI 不仅仅是收取人工智能使用费(API 调用费),而是会从通过其模型(如 GPT)加速的商业成功成果——新药物、材料或产品——中抽取一定比例的收入。 这使 OpenAI 从工具提供商转变为创新合作伙伴,激励其进一步投资于基础人工智能研究。然而,这一想法引发了对知识产权纠纷和用户财务复杂性增加的担忧。 虽然云计算中存在类似模式,但将这种“成果分享”方法应用于人工智能是新颖的。如果实施,它可能会重新定义人工智能竞争,不仅关注技术,还关注控制生态系统并从创新中获益。OpenAI 在将这一雄心勃勃的计划变为现实方面面临重大的法律、伦理和商业挑战,但这表明它正在向解锁更高价值的 B2B 市场迈进。

据报道,OpenAI 计划从利用其人工智能工具进行研发并获得经济收益的客户那里抽取一定比例的利润。这可能包括新药物分子、材料配方、芯片设计,甚至完全由人工智能驱动的新产品等突破性成果。 这一消息引发了争论,许多评论员表达了对它对高科技行业知识产权影响的怀疑和担忧。一些人将其比作“点子人”的不公平主张,而另一些人则质疑鉴于当前围绕大型语言模型输出的版权法,其可执行性。 许多用户对这种交易对公司的吸引力表示怀疑,并预见潜在的法律挑战。一位评论员认为 OpenAI 旨在与客户建立收入分成合资企业,但这种方法的可行性仍不清楚。一些人认为此举是 OpenAI 试图超越广告和投机来将大型语言模型货币化的绝望尝试,可能预示着人工智能领域的转变。
相关文章

原文

In the ongoing exploration of sustainable profit paths, OpenAI is酝酿 a more disruptive business model: taking a share from "AI-Aided Discoveries" achieved by customers using its AI systems. According to insiders, this plan is still under internal discussion but has already attracted widespread attention in high-value R&D fields such as technology, pharmaceuticals, and materials science.

What are "AI-Aided Discoveries"? They refer to innovative outputs accelerated by enterprises or research institutions using OpenAI's large models (such as GPT, Operator agents, etc.)—for example:

- New candidate drug molecules identified by pharmaceutical companies through AI;

- New alloy formulas discovered by material laboratories;

- Optimized circuit architectures developed by chip design teams;

- Even new products incubated by startups based on AI-generated ideas.

OpenAI envisions that if these results achieve commercialization (such as drug launches, patent licensing, product sales), the company would collect a "technology empowerment fee" at a certain percentage. This differs from traditional API usage billing, as it upgrades the charging model from "usage volume" to "value creation," aiming to deeply bind AI with customer success.

If implemented, this move would completely change the relationship between AI service providers and their clients: OpenAI would no longer be just a tool provider, but a **co-sharer in the innovation value chain**. Supporters argue that this could incentivize AI companies to continue investing in high-difficulty basic research; however, critics worry it may lead to disputes over intellectual property ownership and increase the legal and financial complexity for businesses using AI.

Currently, OpenAI has not disclosed specific sharing ratios, applicable scope, or implementation mechanisms. However, considering its annualized revenue reached over $20 billion in 2025, this move may aim to further open up the ceiling of high-value B2B markets—especially in research, biopharmaceuticals, and other fields characterized by "high returns and long cycles."

Notably, similar models already exist in the cloud computing and EDA (Electronic Design Automation) industries, but incorporating AI large models into a "results-sharing" framework is a first. Once implemented, it could reshape the entire AI industry's business logic: **Future AI competition is not only about technology, but also about the struggle for ecosystem sharing rights and innovation influence**.

Between its AGI vision and practical profitability, OpenAI is taking a bold step—but this path is destined to face three major challenges: legal, ethical, and commercial ones.

联系我们 contact @ memedata.com